Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Braz. j. med. biol. res ; 40(11): 1517-1528, Nov. 2007. graf, tab
Article in English | LILACS | ID: lil-464303

ABSTRACT

The effect of different contextual stimuli on different ethanol-induced internal states was investigated during the time course of both the hypothermic effect of the drug and of drug tolerance. Minimitters were surgically implanted in 16 Wistar rats to assess changes in their body temperature under the effect of ethanol. Rat groups were submitted to ethanol or saline trials every other day. The animals were divided into two groups, one receiving a constant dose (CD) of ethanol injected intraperitoneally, and the other receiving increasing doses (ID) during the 10 training sessions. During the ethanol training sessions, conditioned stimuli A (tone) and B (buzzer) were presented at "state +" (35 min after drug injection) and "state -" (170 min after drug injection), respectively. Conditioned stimuli C (bip) and D (white noise) were presented at moments equivalent to stimuli A and B, respectively, but during the saline training sessions. All stimuli lasted 15 min. The CD group, but not the ID group, developed tolerance to the hypothermic effect of ethanol. Stimulus A (associated with drug "state +") induced hyperthermia with saline injection in the ID group. Stimulus B (associated with drug "state -") reduced ethanol tolerance in the CD group and modulated the hypothermic effect of the drug in the ID group. These results indicate that contextual stimuli acquire modulatory conditioned properties that are associated with the time course of both the action of the drug and the development of drug tolerance.


Subject(s)
Animals , Male , Rats , Conditioning, Classical/drug effects , Drug Tolerance/physiology , Ethanol/pharmacology , Hypothermia/chemically induced , Dose-Response Relationship, Drug , Ethanol/administration & dosage , Rats, Wistar
2.
J. bras. med ; 91(5/6): 24-28, nov.-dez. 2006. tab, graf
Article in Portuguese | LILACS | ID: lil-603845

ABSTRACT

O envelhecimento populacional é um fato. As mudanças relacionadas à idade e a presença de múltiplas patologias contribuem para o uso de um maior número de medicamentos pelos idosos, o que por sua vez facilita a ocorrência de reações adversas a drogas (RADs), a quarta causa de óbito nos EUAA. A incidência de RADs varia de 3 por cento a 24 por cento na população geriátrica que procura cuidados médicos de emergência. O número de drogas usadas, o sexo feminino, o número de co-morbidades e a desobediência ao tratamento podem ser considerados fatores relacionados. Antiinflamatórios não-hormonais, diuréticos, inibidores da agregação plaquetária e bloqueadores de canais de cálcio foram as principais drogas associadas. Apesar da heterogeneidade dos dados encontrados, as RADs representa um importante problema, não somente clínico, mas também socioeconômico.


Subject(s)
Humans , Aged , Platelet Aggregation , Anti-Inflammatory Agents, Non-Steroidal , Calcium Channel Blockers/adverse effects , Diuretics/adverse effects , Drug-Related Side Effects and Adverse Reactions , Patient Compliance/psychology , Treatment Refusal , Drug Tolerance/physiology
3.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 28(1): 18-23, mar. 2006. ilus
Article in English, Portuguese | LILACS | ID: lil-435707

ABSTRACT

OBJETIVE: It has been shown that neurosteroids can either block or stimulate the development of chronic and rapid tolerance to the incoordination and hypothermia caused by ethanol consumption. The aim of the present study was to investigate the influence of isopregnanolone on the development of rapid tolerance to the anxiolytic effect of ethanol in mice. METHOD: Male Swiss mice were pretreated with isopregnanolone (0.05, 0.10 or 0.20 mg/kg) 30 min before administration of ethanol (1.5 g/kg). Twenty-four hours later, all animals we tested using the plus-maze apparatus. The first experiment defined the doses of ethanol that did or did not induce rapid tolerance to the anxiolytic effect of ethanol. In the second, the influence of pretreatment of mice with isopregnanolone (0.05, 0.10 or 0.20 mg/kg) on rapid tolerance to ethanol (1.5 g/kg) was studied. CONCLUSIONS: The results show that pretreatment with isopregnanolone interfered with the development of rapid tolerance to the anxiolytic effect of ethanol.


OBJETIVO: Estudos prévios têm mostrado que os neuroesteróides podem bloquear ou estimular o desenvolvimento da tolerância rápida e crônica aos efeitos de incoordenação e hipotermia produzidos pelo etanol. O objetivo do presente estudo foi investigar a influência da isopregnenolona sobre o desenvolvimento da tolerância rápida ao efeito ansiolítico do etanol em camundongos. MÉTODO: Camundongos suíços, machos, foram pré-tratados com isopregnenolona (0,05, 0,10 ou 0,20 mg/kg) 30 minutos antes da administração de etanol (1,5 g/kg). Após 24 horas, todos os animais foram testados no labirinto em cruz elevado. O primeiro experimento foi realizado com o intuito de selecionar uma dose de etanol que produzisse tolerância rápida ao efeito ansiolítico do etanol. No segundo experimento, o objetivo foi investigar o efeito da isopregnenolona (ISO; 0,05, 0,10 ou 0,20 mg/kg) sobre a tolerância rápida ao etanol (1,5 g/kg). CONCLUSÕES: Os resultados mostram que o tratamento prévio com isopregnenolona interferiu no desenvolvimento da tolerância rápida ao efeito ansiolítico etanol.


Subject(s)
Animals , Male , Mice , Anti-Anxiety Agents/adverse effects , Ataxia/chemically induced , Ethanol/adverse effects , Hypothermia/chemically induced , Pregnenolone/adverse effects , Drug Tolerance/physiology , Analysis of Variance , Maze Learning/drug effects , Motor Activity/drug effects , Receptors, GABA-A/drug effects
5.
Article in English | IMSEAR | ID: sea-45313

ABSTRACT

INTRODUCTION: The correction of hyperglycemia by insulin treatment has been shown to ameliorate beta cell function and insulin sensitivity in SU failure patients, and there also appears to have disparity between tests of beta cell function among these patients. The objectives of this study were to determine beta cell secretory reserve and insulin resistance of secondary SU failure type 2 diabetic patients who had fairly good glycemic control compared with those who were SU responsive and the disparity of beta cell responses to glucose and non-glucose stimuli were examined in these two groups. SUBJECTS AND METHOD: Eight secondary SU failure, insulin-treated and 11 SU responsive type 2 diabetic patients who were matched for age, degree of obesity, duration of diabetes as well as HbAlc were studied. Intravenous glucagon and oral glucose tolerance tests (OGTT) as well as short intravenous insulin tolerance test using arterialized venous blood were randomly performed on separate occasions to assess beta cell secretory reserve and insulin sensitivity, respectively. RESULTS: Basal (0.37+/-0.05 (SEM) vs 0.80+/-0.14 nmol/l; p=0.02) and stimulated c-peptide levels (0.66+0.08 vs 1.16+/-0.14 nmol/l; p=0.007) after glucagon as well as basal (0.46+/-0.06 vs 0.73+/-0.10 nmol/l; p=0.046) and maximal c-peptide responses (1.41+/-0.14 vs 1.97+/-0.14 nmol/l; p=0.021) to glucose stimulation were significantly lower in SU failure than SU responsive patients. However, the incremental changes of c-peptide over basal after glucagon (0.29+/-0.06 vs 0.37+/-0.09 nmol/l) and glucose (AUC: 36.9+/-7.6 vs 47.9+/-4.5 nmol/l/h) were not different between both groups. There were strong positive relationships between basal and stimulated c-peptide responses to glucagon (r=0.818; p=0.002) and glucose (r=0.85; p=0.001) in SU responsive patients but these relationships were not as strong in SU failure patients (r=0.682; p=0.062 and r=0.41; p=NS, respectively). Insulin sensitivity did not differ between the two groups. CONCLUSION: This study demonstrated that decreased basal, but not stimulated, insulin secretion was possibly a major factor associated with secondary SU failure in type 2 diabetic patients. With comparable glycemic control, there was no disparate beta cell responses to glucose and glucagon in patients with or without secondary SU failure.


Subject(s)
Aged , Diabetes Mellitus, Type 2/physiopathology , Drug Tolerance/physiology , Female , Humans , Insulin Resistance/physiology , Islets of Langerhans/physiopathology , Male , Middle Aged , Sulfonylurea Compounds/pharmacology
7.
Rev. argent. anestesiol ; 59(1): 54-66, ene.-feb. 2001.
Article in Spanish | LILACS | ID: lil-288448

ABSTRACT

Introducción: las primeras crónicas históricas sobre el empleo humano de los alcaloides del opio concuerdan en afirmar que lo que más llamó la atención de sus descubridores fueron sus propiedades euforizantes y narcóticas antes que sus efectos terapéuticos. Con el tiempo, el desarrollo de nuevos derivados, los descubrimientos acerca de los mecanismos de acción del sistema endógeno opioide y su relación con la fisiología y la fisiopatología del dolor, y la constitución de mejores modelos experimentales para el estudio de nuevos prototipos de drogas y sus mecanismos, permitieron optimizar el empleo terapéutico de esta herramienta fundamental en el tratamiento del dolor. Sin embargo, la posibilidad del desarrollo del fenómeno de tolerancia y el temor a provocar en el paciente dependencia y adicción conspiran todavía contra un aprovechamiento total de este recurso terapéutico. Objetivos: los objetivos del presente artículo son: revisar los conceptos y mecanismos involucrados en la analgesia, la tolerancia (aguda o crónica), la dependencia y la adicción a las drogas opioideas; poner al día los hallazgos en el terreno de la investigación clínica y básica sobre la producción de tolerancia, analgesia, hiperalgesia y supersensibilidad, además del descubrimiento de los principios farmacológicos que retardan o impiden la aparición del fenómeno de tolerancia; y rever las teorías que explican dichos fenómenos en relación a lo que acontece en la práctica clínica diaria. Discusión: si bien la tolerancia crónica es un fenómeno que no siempre se evidencia en la práctica clínica, especialmente en el tratamiento del dolor no oncológico, se trata de un proceso farmacodinámicamente posible y demostrado experimentalmente tanto en animales como en seres humanos. Más aún, con los nuevos opioides de corta vida media, administrados en infusión continua durante la anestesia, incluso es posible la ocurrencia de tolerancia aguda. Si bien los mecanismos, involucrados en la génesis de la tolerancia están relacionados con los que pueden generar dependencia y drogadicción, sólo en casos excepcionales un paciente con dolor tratado con opioides se convierte en un adicto. Se revisan aquí los tipos de tolerancia posible, las teorías sobre su desarrollo, los hallazgos experimentales que las avalan, las controversias existentes sobre algunos puntos (factores farmacocinéticos y farmacodinámicos, receptores opioides involucrados...


Subject(s)
Animals , Rats , Humans , Drug Tolerance/physiology , Narcotics/administration & dosage , Narcotics/therapeutic use , Opioid-Related Disorders , Pain/physiopathology , Pain/therapy , Patients/psychology , Neoplasms/therapy
8.
Indian J Physiol Pharmacol ; 2001 Jan; 45(1): 111-5
Article in English | IMSEAR | ID: sea-108933

ABSTRACT

Differential degree of tolerance has been reported to develop for anticonvulsant, sedative and skeletal muscle relaxant effects of benzodiazepines (BZDs). Acute treatment with BZDs reportedly reduces the formation of gastric stress ulcers and attenuates stress-induced immunosuppression. The present study investigates whether tolerance develops to these antistress effects of BZDs by using diazepam and chlordiazepoxide as representative drugs. A single dose of diazepam (5 mg/kg, i.p.) or chlordiazepoxide (20 mg/kg, i.p.) produced a significant reduction in locomotor activity, a measure of sedative effect and antagonized the effect of restraint stress (RS) on gastric mucosal lesions and anti-sheep red blood cell (SRBC) antibody titre. With chronic treatment (X 7 d), there was a marked tolerance to the sedative effect of both the studied BZD drugs, while much less tolerance developed to their ulcer protective action. However, no tolerance was observed to the attenuating effect of diazepam and chlordiazepoxide on RS-induced immunosuppression. Thus, the results of the present study indicate that different mechanisms may be involved in the development of tolerance to the sedative, antiulcer and immunomodulatory effects of BZDs.


Subject(s)
Animals , Anti-Anxiety Agents/pharmacology , Benzodiazepines/pharmacology , Chlordiazepoxide/pharmacology , Diazepam/pharmacology , Drug Tolerance/physiology , Gastric Mucosa/drug effects , Hypnotics and Sedatives/pharmacology , Male , Motor Activity/drug effects , Rats , Stomach Ulcer , Stress, Physiological/blood
9.
Rev. enfermedades infecc. ped ; 14(53): 16-22, jul.-sept. 2000. tab, graf, CD-ROM
Article in Spanish | LILACS | ID: lil-292304

ABSTRACT

La otitis media aguda (OMA) es motivo de consulta frecuente en la práctica pediátrica y otorrinolaringológica. Los antibióticos betalactámicos son agentes de elección para el tratamiento de la OMA de etiología bacteriana, pero la creciente aparición de cepas productoras de betalactamasas obliga a asociarlos con un inhibidor de las mismas. Objetivos: evaluar efectividad y tolerabilidad de amoxicilina + sulbactam, administrada cada 12 horas en lactantes y niños portadores de OMA de etiología presumiblemente bacteriana. Material y métodos: estudio abierto, multicéntrico. Los pacientes recibieron amoxicilina + sulbactam (50/50 mg/kg/d) en dosis repartida en dos tomas diarias durante 10 días. Se evaluó (días 1, 4, 10 y 40): otalgia, hipertermia, irritabilidad y otorrea. Se efectuó otomicroscopía; en casos necesarios miringotomía terapéutica y para rescate de gérmenes, y se controló la aparición de eventos adversos. Se determinó efectividad clínica y tolerabilidad. Resultados: siete centros incorporaron a 222 pacientes evaluables. En 41 se efectuó miringotomía, aislándose con mayor frecuencia S. pneumoniae, H. influenzae, y M. catarrhalis. Se produjo una reducción de la otalgia entre el día 0 y el 10, de 6.8 ñ 0.11 a 2.3 ñ 0.09 (p< 0.001), así como también una mejoría significativa de la curva térmica. Se presentaron eventos adversos en 76 pacientes, la mayoría vinculados al aparato digestivo, en todos los casos de intensidad leve a moderada. Al finalizar el periodo de tratamiento todos los pacientes se habían curado o mejorado clínicamente. Conclusiones: Amoxicilina/sulbactam en dosis fraccionada cada 12 horas fue eficaz y segura para el tratamiento de la OMA en niños.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Amoxicillin/therapeutic use , Drug Therapy, Combination/pharmacokinetics , Otitis Media/drug therapy , Sulbactam/therapeutic use , Drug Tolerance/physiology
10.
Arq. bras. endocrinol. metab ; 44(2): 139-43, abr. 2000. tab
Article in Portuguese | LILACS | ID: lil-259841

ABSTRACT

Cabergolina (CAB, Pharmacia) é um agonista dopaminérgico derivado do ergot com longa ação após administração oral, que já tem demonstrado ser de utilidade para o tratamento da hiperprolactinemia. Quarenta e cinco pacientes (36 mulheres, 9 homens) com prolactinomas (27 micro, 18 macro), intolerantes e/ou resistentes à bromocriptina (BRC) foram tratados com dose semanal de CAB de 0,25 a 7mg (mediana: 1mg) dividida de 1 a 7 administrações. O tratamento, em compassionate basis, variou de 1 a 38 meses (mediana: 12 meses). Entre os 38 pacientes com intolerância persistente à BRC (sintomas digestivos, n=27; hipotensão postural, n=13; congestão nasal, n=5; manifestações psiquiátricas, n=4; retenção urinária, n=1), somente 5 permaneceram intolerantes à CAB (sintomas digestivos, n=2; hipotensão postural, n=2; congestão nasal, n=1). Todos aqueles que toleraram bem a BRC também o fizeram com CAB. Onze casos alcançaram normalização da prolactina durante o uso de BRC. Estes pacientes e outros 19 também resolveram a hiperprolactinemia com CAB. Entretanto, somente 3 dos 7 pacientes resistentes (dose diária de BRC de 10 a 25mg) tiveram a prolactina sérica normalizada durante o uso de CAB. Redução tumoral foi documentada por ressonância mag-nética ou tomografia computadorizada em 7 macroprolactinomas durante o tratamento com CAB. Assim, devido à sua excelente eficácia, tolerabilidade e comodidade posológica, a CAB apresenta-se como importante alternativa no tratamento clínico dos prolactinomas.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Bromocriptine/therapeutic use , Ergolines/therapeutic use , Prolactinoma/drug therapy , Dopamine Antagonists/therapeutic use , Drug Tolerance/physiology , Drug Resistance/physiology
13.
Invest. med. int ; 24(3): 77-84, ene.-mar. 1998. graf
Article in Spanish | LILACS | ID: lil-245297

ABSTRACT

Con el objetivo de valorar la seguridad, tolerancia y eficacia de ketoprofeno más clorzoxazona vs diclofenaco en pacientes con síndrome doloroso de la columna vertebral, se realizó un estudio clínico doble ciego, prospectivo, longitudinal, controlados e inferencial. Para ellos, se incluyeron 50 pacientes que se distribuyeron en dos grupos: el A recibió dosis diaria de 50 mg de ketoprofeno más 250 clorzoxazona dos veces al día desde el inicio hasta el final del estudio, y el B 200 mg de diclofenaco al día. Se realizó examen clínico el día cero y 15 del tratamiento y luego periódicamente hasta un total de 12 semanas. Posterior a dicho periodo, en la primera evaluación se observó diferencia entre los grupos de tratamiento. En el grupo tratado con ketoprofeno más clorzoxazona disminuyó el dolor a la palpación, movimiento e inflamación y mejoró la función articular, no así con diclofenaco. Se observaron diferencias entre los dos grupos, tanto en el tratamiento como en respuesta sintomatológica que fueron significativas durante el estudio. Después de ocho semanas de tratamiento 70 por ciento del grupo con ketoprofeno más con diclofenaco. Estas sifras aumentaron hasta 95 por ciento de recuperacion casi completa en el grupo de ketoprofeno más clorzoxazona, mientras que 70 por ciento del grupo con diclofenaco no mejoró en absouluto como lodemuestran las estadísticas de respuesta. En ambos casos, la diferencia fue estadísticamente significativa. La tolerancia de ketoprofeno más clorzoxazona se consideró excelente. En ambos grupos se observaron incidencias similares de irritación gástrica en 4 por ciento de los casos. Estos resultados confirman la excelente seguridad, toleranacia y eficacia de ketoprofeno más clorzoxazona en el tratamiento del síndrome doloroso de la columna vertebral


Subject(s)
Humans , Male , Female , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Chlorzoxazone/therapeutic use , Diclofenac/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Drug Tolerance/physiology , Longitudinal Studies , Pain/diagnosis , Prospective Studies , Spine/anatomy & histology
14.
Braz. j. med. biol. res ; 30(6): 775-82, jun. 1997. tab, graf
Article in English | LILACS | ID: lil-194179

ABSTRACT

Opiates have been implicated in learned helplessness (LH), a phenomenon known to be related to opiate stress-induced analgesia (SIA). In the present study, we investigated the role of opiates in the induction of LH and SIA under different conditions. Adult female Wistar rats were trained either by receiving 60 inescapable 1-mA footshocks (IS group, N = 114) or by confinement in the shock box (control or NS group, N = 92). The pain threshold of some of the animals was immediately evaluated in a tail-flick test while the rest were used 24 h later in a shutttle box experiment to examine their escape performance. The opiate antagonist naltrexone (0 or 8 mg/kg, ip) and the previous induction of cross-tolerance to morphine by the chronic administration of morphine (0 or 10 mg/kg, sc, for 13 days) were used to identify opiate involvement. Analysis of variance revealed that only animals in the IS group demonstrated antinociception and an escape deficit, both of which were resistant to the procedures applied before the training session. However, the escape deficit could be reversed if the treatments were given before the test session. We conclude that, under our conditions, induction of the LH deficit in escape performance is not opiate-mediated although its expression is opiate-modulated.


Subject(s)
Rats , Animals , Female , Analgesia , Analgesics, Opioid/pharmacology , Drug Tolerance/physiology , Helplessness, Learned , Morphine/metabolism , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Rats, Wistar
15.
Rev. méd. IMSS ; 35(1): 79-84, ene.-feb. 1997. tab
Article in Spanish | LILACS | ID: lil-226778

ABSTRACT

Tres de los inhibidores selectivos de la recaptura de serotonina estarán disponibles para el uso de los pacientes psiquiátricos atendidos en el Instituto Mexicano del Sguro Social, por lo que consideramos interesante revisar algunos de los aspectos que los diferencian entre sí y de los antidepresivos tricíclicos tradicionales. Los inhibidores selectivos de la recaptura de serotonina son psicofármacos antidepresivos que han mostrado la capacidad de inhibir potente y selectivamente la recaptura de serotonina (5-hidroxitriptamina), una indolamina que participa en una serie de situaciones clínicas de gran importancia particularmente en psiquiatría, como trastornos efectivos, ansiosos, obsesivo compulsivos, alcoholismo, control de impulsos y conducta alimentaria, por mencionar algunos. Se describen las caracteristícas farmacocinéticas, farmacodinámicas, efectos colaterales y perfiles terapéuticos de los inhibidores selectivos de la recaptura de serotonina, comparándolos con los antidepresivos tricíclicos tradicionales. Se analizan los motivos por los que se consideran fármacos de mayor seguridad y torabilidad, especialmente en el paciente médicamente enfermo con comorbilidad psiquiátrica asociada


Subject(s)
Psychiatry , Serotonin , Treatment Outcome , Drug Tolerance/physiology , Antidepressive Agents/adverse effects , Antidepressive Agents/metabolism , Antidepressive Agents/therapeutic use , Antidepressive Agents/pharmacology , Antidepressive Agents/pharmacokinetics , Nervous System
16.
Braz. j. med. biol. res ; 29(11): 1415-26, Nov. 1996.
Article in English | LILACS | ID: lil-187198

ABSTRACT

Several experimental models have been used to study tolerance to ethanol. The development of tolerance to the motor incoordinating effect of a single administration of ethanol occurs within 8-24 h after the effect of the first dose has disappeared. This form of tolerance is designated rapid tolerance and seems to involve functional rather than pharmacokinetic mechanisms. Like chronic tolerance, rapid tolerance has been shown to be infiuenced by processes related to learning and memory. It is known that N-methyl-D-aspartate (NMDA) receptor systems are involved in the expression and maintenance of one form of long-term potentiation (LTP), a synaptic adaptive process which has been suggested to be the cellular basis of memory or associative memory. Considering the similarities between learning and tolerance, the effects of NMDA agonists and antagonists on tolerance to ethanol were investigated. Our studies demonstrated that NMDA antagonists that impair learning, such as dizocilpine or ketamine, inhibit tolerance, while NMDA agonists that improve learning, such as D-cycloserine, increase tolerance. Moreover, the nitric oxide synthase inhibitor L-nitroarginine blocks tolerance to the effects of ethanol. Taken together, these data confirm the involvement of the NMDA system in ethanol tolerance and emphasize the participation of leaming in this phenomenon.


Subject(s)
Dizocilpine Maleate/pharmacology , Ethanol/pharmacology , Ketamine/pharmacology , Nitric Oxide/pharmacology , Receptors, N-Methyl-D-Aspartate/drug effects , Serotonin/pharmacology , Drug Tolerance/physiology , Receptors, Glutamate/drug effects
17.
Rev. méd. IMSS ; 34(5): 421-7, sept.-oct. 1996. tab
Article in Spanish | LILACS | ID: lil-203044

ABSTRACT

Para determinar la frecuencia de reacciones adversas a medicamentos en niños hospitalizados, se realizó un estudio observacional de farmacovigilancia en pacientes pediátricos en dos hospitales del segundo nivel ubicados en el Distrito Federal. Se hizo un seguimiento de la estancia hospitalaria de 395 pacientes pediátricos. Para la valoración de las reacciones adversas potenciales, se utilizó el algoritmo de Kramer y colaboradores, que consta de 56 preguntas. Se consideraron con sospecha de reacción adversa a los medicamentos 13 pacientes, 10 de ellos fueron calificados con reacción adversa probable y uno con reacción adversa definitiva. La frecuencia de reacciones adversas en cuatro meses fue de 3 por ciento, lo que es comparable con otros datos publicados en la literatura especializada. Se comenta la conveniencia de incluir este algoritmo en programas de farmacovigilancia de mayor escala, al menos como discernimiento inicial para la aplicación de otras técnicas analíticas de mayor costo.


Subject(s)
Infant , Child, Preschool , Child , Humans , Male , Female , Pediatrics , Pharmaceutical Preparations/adverse effects , Drug Antagonism , Drug Incompatibility , Drug Tolerance/physiology , Medication Errors/classification , Pharmacokinetics
18.
An. bras. dermatol ; 70(3): 195-8, maio-jun. 1995. ilus, tab
Article in Portuguese | LILACS | ID: lil-175836

ABSTRACT

Fundamento - O itraconazol é um derivado traiazólico de amplo espectro de açäo. Objetivo - Avaliar a eficácia e tolerabilidade do itraconazol no tratamento da pitiríase versicolor, em estudo multicêntrico aberto, näo comparativo. Métodos - Foram analisadas 333 fichas de pacientes que receberam duas cápsulas de 100mg da droga, por via oral, uma vez ao dia durante cinco dias. A diagnose clínica foi comprovada por exame com luz de Wood e exame micológico direto. Os pacientes foram submetidos a avaliaçöes clínica e micológica no pré-tratamento e 30 dias após o término do tratamento. Resultados - Observou-se cura micológica em 93,7 por cento dos casos. A tolerabilidade foi considerada boa, tendo sido registrados efeitos colaterais leves em 5,7 por cento dos pacientes. Conclusäo - O itraconazol mostrou ser uma droga efetiva e segura para o tratamento da pitiríase versicolor


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Drug Evaluation/methods , Drug Tolerance/physiology , Itraconazole/therapeutic use , Pityriasis/diagnosis , Pityriasis/drug therapy , Malassezia
SELECTION OF CITATIONS
SEARCH DETAIL